rss
BMJ Qual Saf 23:95-98 doi:10.1136/bmjqs-2013-002276
  • Viewpoint

Unintentional non-adherence: can a spoon full of resilience help the medicine go down?

Open Access
  1. Ann Blandford1
  1. 1UCL Interaction Centre (UCLIC), University College London, London, UK
  2. 2Department of Practice and Policy, Centre for Medication Safety and Service Quality, UCL School of Pharmacy, London, UK
  3. 3Faculty of Medicine, Centre for Haematology (Honorary Research Associate), Imperial College London, London, UK
  4. 4Atlantis Healthcare (Clinical Strategist), London, UK
  1. Correspondence to Dr Dominic Furniss, UCL Interaction Centre (UCLIC), University College London, MPEB 8th Floor, Gower Street, London, WC1E 6BT, UK; d.furniss{at}ucl.ac.uk
  • Received 1 July 2013
  • Revised 15 August 2013
  • Accepted 17 August 2013
  • Published Online First 16 September 2013

INTRODUCTION

Non-adherence to medication is a ‘worldwide problem of striking magnitude’.1 It has consequences for the health of patients and is a great concern for healthcare providers in terms of patient outcomes and healthcare costs. Theoretical research has mainly focused on intentional non-adherence: for example, when people choose not to take their medication. However, unintentional non-adherence also accounts for a significant proportion of the problem: when people mean to take their medication in the right way but do not. This area is under-researched. In this paper, we bring a new perspective to this problem by exploring what contribution ‘resilience’ could make to it. Resilience engineering focuses on a system's ability to maintain performance, avoid error, compensate for poor circumstances and cope with disturbances. So, rather than focus on how things go wrong, we propose to exploit and enhance how things go right.

Non-adherence

The National Health Service in England processed 962 million prescriptions in 2011, which had an ingredient cost of £8.8 billion,2 and it is estimated that 30%–50% of prescribed medication are not taken correctly.3 A report prepared for a summit of European health ministers in 2012 estimated that non-adherence contributes approximately 57% of $500 billion total avoidable costs attributed to suboptimal medicine use globally each year.4 Horne et al3 provide a broad and comprehensive review of the research in this area. Their report shows that the problem is complex and multifaceted, and they call for more research to tackle this important issue. They argue that improving the effectiveness of adherence interventions could have a greater impact on public health than improvements in specific medical treatments.3

Haynes et al5 note that current successful interventions for non-adherence are multifaceted, complex, labour intensive and at best have modest effects; they call for innovative approaches to assist …

Open Access

Free sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BMJ Quality & Safety.
View free sample issue >>

Email alerts

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

 

Navigate This Article